Overview: Haptoglobin TestIntroduction: The Haptoglobin Test measures haptoglobin levels to diagnose hemolytic anemia, causing fatigue or jaundice. Aligned with 2023 ASH guidelines, it uses an immunoassay for high sensitivity, aiding in hematological screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in immunology for patients with suspected hemolysis, such as in sickle cell disease or autoimmune disorders.
Other Names: Haptoglobin Assay, Hemolysis Marker Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: Haptoglobin testing began in the 1960s with hemolysis research. Immunoassays improved in the 1980s, enhancing accuracy for anemia diagnosis.
Purpose: Diagnoses hemolytic anemia, guides treatment, and monitors haptoglobin levels in patients with fatigue, jaundice, or pallor.
Test Parameters: 1. Haptoglobin
Pretest Condition: No fasting required. Collect serum or plasma at any time. Report symptoms like fatigue or jaundice, and list medications.
Specimen: 2-5 mL serum (SST) or 2-4 mL plasma (EDTA). Centrifuge within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document fatigue, jaundice, pallor, or history of hemolytic anemia. Include current medications, especially immunosuppressants, and recent transfusions.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for anemia treatment.
Procedural Considerations: Uses an immunoassay to measure haptoglobin levels. Results are available in 1-2 days, enabling rapid clinical decisions.
Factors Affecting Result Accuracy: Hemolysis, recent transfusions, or inflammation (e.g., acute phase response) can affect results. Liver disease may alter levels.
Clinical Significance: Low haptoglobin levels suggest hemolytic anemia, prompting further testing or treatment. Normal levels may require additional evaluation.
Specialist Consultation: Consult a hematologist for result interpretation and anemia management.
Additional Supporting Tests: LDH, reticulocyte count, bilirubin, or peripheral smear to confirm hemolytic anemia.
Test Limitations: Non-specific reductions may occur in liver disease or inflammation. Results require clinical correlation.
References: ASH Hemolytic Anemia Guidelines, 2023; Blood, Schrier SL, 2022.
